MedTrace Logo

Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients

NCT00742976 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-01-20

No results posted yet for this study

Summary

Hypothesis: Changing type 2 patients treatment from Insulin Insulatard to Insulin Detemir will increase their excretion of sodium in the urine and thereby decrease their extracellular volume and body weight. 24 patients are divided into 2 groups and their insulin treatment is shifted while their body composition, sodium excretion, weight and extracellular volume is monitored.

Conditions

  • Diabetes Type 2
  • Weight Gain

Interventions

DRUG

Insulin Detemir; Insulin Insulatard

Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.

DRUG

Insulin Detemir, Insulin Insulatard

Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Tonny Jensen, M.D MSci. · Dept of Endocrinology at Rigshospitalet, Copenhagen.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00742976 on ClinicalTrials.gov